bupropion and tirzepatide Tirzepatide and Graves Disease: Safety and Clinical Considerations

Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits

21.32

★★★★☆4.8 (126)

Enhanced weight loss outcomes with GLP-1 analogues and bupropion/naltrexone combination

29.29

★★★★★4.9 (98)

RETRACTED ARTICLE: Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study

24.54

★★★★★5.0 (157)

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort

29.46

★★★★★4.7 (84)

In a patient taking bupropion 100 mg daily, buspirone 1 mg nightly, tirzepatide 2.5 mg weekly, rosuvastatin 5 mg every other day, ezetimibe 10 mg daily, ibuprofen as needed, baclofen 5–10 mg

20.64

★★★★★4.9 (203)

A first-in-human study suggested that tirzepatide — a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist — modulated abnormal activity in the brain's nucleus accumbens, thereby reducing food cravings and inducing

28.33

★★★★★5.0 (176)

A systematic review and meta-analysis of clinical trials investigating the efficacy and safety of obesity management medications reports that tirzepatide and semaglutide are the most effective in reducing body weight and obesity-related

25.50

★★★★★4.8 (132)